Spin-out of Monument Therapeutics
Insights Back to resource centre 1 July 2021 Spin-out of Monument Therapeutics Cambridge Cognition is pleased to announce the completion of the spin-out of Monument Therapeutics, a drug development company applying digital phenotyping to central nervous system (“CNS”) disorders. Cambridge Cognition has been incubating Monument Therapeutics since 2018, with early-stage research supported by two Innovate UK grants. Monument Therapeutics applies
Spin-out of Monument Therapeutics Read More »





